FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to compounds of formula I, as well as to use thereof as a pharmaceutical agent for treating cancer and a method for production thereof.
(I).
EFFECT: obtaining compounds capable of inhibiting cytosolic thioredoxin reductase applicable in treating mediated diseases, such as cancer.
12 cl, 17 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TRICYCLIC COMPOUNDS AND USE THEREOF FOR TREATING CANCER | 2016 |
|
RU2736501C2 |
| HETEROARYLSULPHONYL-SUBSTITUTED PYRIDINES AND APPLICATION THEREOF IN TREATMENT OF CANCER | 2018 |
|
RU2772935C2 |
| HETEROCYCLYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN TREATMENT OF CANCER | 2018 |
|
RU2777596C2 |
| N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
| N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
| ENPP1 INHIBITORS AND METHODS OF MODULATING THE IMMUNE RESPONSE | 2018 |
|
RU2800798C2 |
| HETEROCYCLIC IMMUNOMODULATORS AS INHIBITOR OF IMMUNE RESPONSE CHECKPOINTS PDL1 | 2020 |
|
RU2824127C2 |
| VET PROTEIN DECOMPOSERS | 2017 |
|
RU2752677C2 |
| ANTIBODY-STING AGONIST CONJUGATES AND USE THEREOF IN IMMUNOTHERAPY | 2020 |
|
RU2826228C2 |
| MDM2 PROTEIN DESTRUCTORS | 2017 |
|
RU2743432C2 |
